OVB Ovoca Bio Plc

TIDMOVB

Ovoca Bio PLC

07 November 2019

Ovoca Bio plc

("Ovoca" or the "Company")

Attendance at BIO-Europe Conference

Dublin, Ireland, November 7, 2019 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, today announces that the Company will be attending the 25(th) annual BIO-Europe Partnering Conference, taking place from 11-13 November 2019, in Hamburg, Germany.

Management will host one-on-one meetings with investors at the Conference. To inquire about arranging a meeting with management, please contact Dr Daniel Nemenov, at Ovoca Bio.

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Advisor and Broker)

John Frain / Daragh O'Reilly

Tel: +353 1 679 6363

Consilium Strategic Communications

Chris Gardner, Chris Welsh, Carina Jurs

ovocabio@consilium-comms.com

Tel: +44 (0)20 3709 5700

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated 4 million premenopausal women in the US alone.

The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.

Ovoca Bio has filed for approval for the marketing of BP-101 in Russia and is seeking to develop the drug for major global markets - in particular the United States and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUGGQPGUPBGPM

(END) Dow Jones Newswires

November 07, 2019 07:45 ET (12:45 GMT)

Grafico Azioni Ovoca Bio (LSE:OVB)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Ovoca Bio (LSE:OVB)
Storico
Da Apr 2023 a Apr 2024